Results 61 to 70 of about 5,967 (167)
Genetic Mutations in Recurrent/Metastatic Papillary Thyroid Carcinoma
We investigated the mutational landscape and prognostic implications of recurrent/metastatic papillary thyroid carcinoma using nationwide C‐CAT data from 348 patients. CDKN2A, KMT2D, and concurrent TERT/BRAF mutations were independently associated with poorer overall survival, highlighting the potential prognostic value of comprehensive genomic ...
Hiromi Nagano +3 more
wiley +1 more source
The FGF/FGFR System in the Biology and Therapeutic Landscape of Pediatric CNS Tumors
ABSTRACT Central nervous system (CNS) tumors are the most common solid malignancies in children, comprising a highly heterogeneous group of neoplasms defined by distinct molecular alterations and clinical behaviors. Advances in molecular genetics have underscored the relevance of specific signaling pathways in driving pediatric tumorigenesis, among ...
Serena Filiberti +6 more
wiley +1 more source
Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients
Neurotrophic tyrosine receptor kinase gene fusions (NTRK) are oncogenic drivers present at a low frequency in most tumour types (80%) in a small number of rare tumours (e.g., infantile fibrosarcoma [IFS]) and considered mutually exclusive with other ...
Sébastien Perreault +10 more
doaj +1 more source
The translational pipeline of precision medicine in clinical oncology. Schematic overview of the individualized cancer care workflow. (1) Input: Patient samples undergo multi‐omic profiling via NGS, single‐cell diagnostics, spatial maps, and epigenetic sequencing.
Asif Jan +3 more
wiley +1 more source
DNA methylation profiling identifies GPAP as a distinct circumscribed glioma with a characteristic expansive, multicystic radiological appearance, pleomorphic and pseudopapillary histology, a recognizable CNV profile, druggable molecular alterations, and recurrent cancer predisposition syndromes.
Alberto Picca +35 more
wiley +1 more source
Background Receptor tyrosine kinase (RTK) inhibitors have been approved for the treatment of NTRK fusion (NTRK+) and RET fusion (RET+) positive solid tumors in a tumor‐agnostic manner. However, the objective response rate was the lowest among entrectinib‐
Zhaohui Liao Arter +3 more
doaj +1 more source
This nationwide survey reveals that comprehensive multigene testing for advanced NSCLC has rapidly expanded in Japan, steadily increasing the use of targeted therapies for rare oncogenic drivers. Despite these diagnostic advancements, approximately 30% of patients consistently remain untested, highlighting a persistent clinical gap in real‐world ...
Satoshi Ikeda +9 more
wiley +1 more source
Triple‐negative breast cancer (TNBC) is usually an aggressive disease with a poor prognosis and limited treatment options. The neurotrophic tyrosine receptor kinase (NTRK) gene fusions are cancer type‐agnostic emerging biomarkers approved by the Food and
Federica Zito Marino +13 more
doaj +1 more source
Figure 6 Comprehensive genomic profiling identified additional actionable alterations in a substantial proportion of patients with non‐squamous NSCLC despite previously identified driver alterations, with some findings leading to subsequent matched targeted therapies.
Yoshihiro Masui +15 more
wiley +1 more source
PDGFD‐Rearranged Dermatofibrosarcoma Protuberans With S100 and Pan‐TRK Expression
ABSTRACT Dermatofibrosarcoma protuberans (DFSP) is a fibroblastic malignancy characterized in most cases by COL1A1::PDGFB fusion. Rare cases exhibit alternative rearrangements involving PDGFD. Here, we describe a female patient in her third decade of life who presented with a spindle cell proliferation on the shoulder.
Venezia Podesta +4 more
wiley +1 more source

